The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis

Current Medical Research and Opinion

Volumn 27, Issue 3, 2011, Pages 623-631

  Torkildsen, Gail ^a   Shedden, Arthur ^b  

^a Andover Eye Associates   (United States)

^b Vistakon   (United States)

Author keywords

Antihistamine; CAC Conjunctival allergen challenge; Itch; Ocularredness; Once daily dosing

Indexed keywords

ALCAFTADINE; ALLERGEN; EYE DROPS; PLACEBO;

ALLERGIC CONJUNCTIVITIS; ARTICLE; BRONCHITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOSSODYNIA; HUMAN; MALE; MULTICENTER STUDY; NORMAL HUMAN; OCULAR PRURITUS; PHASE 3 CLINICAL TRIAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLIT LAMP; TOOTH PAIN; VISUAL ACUITY; XEROPHTHALMIA;

ADULT; BENZAZEPINES; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PLACEBOS; PRURITUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951611143     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.548797     Document Type: Article

References (24)

1. Ciprandi G, Buscaglia S, Cerqueti PM, et al. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs 1992;43:154-76
2. Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease subtypes, treatment. Ocul Surf 2003;1:127-49 (Pubitemid 41263901)
3. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112:15-22 (Pubitemid 36819801)
4. Rondon C, Fernandez J, Canto G, et al. Local allergic rhinitis: concept, clinical manifestations, and diagnostic approach. J Investig Allergol Clin Immunol 2010;20:364-71
5. Udell IJ, Abelson MB. Animal and human ocular surface response to a topical nonimmune mast-cell degranulating agent (compound 48/80). Am J Ophthalmol 1981;91:226-30 (Pubitemid 11184485)
6. Smith JA, Mansfield LE, de Shazo RD, et al. An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. J Allergy Clin Immunol 1980;65:118-21 (Pubitemid 10131160)
7. Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol 1981;99:302-4
8. Physicians' Desk Reference for Ophthalmic Medications, 32nd edn. Montville, NJ: Thomson PDR, 2004
9. Guest JF, Davie AM, Ruiz FJ, et al. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005;14:88-98 (Pubitemid 40410057)
10. Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76:448-54 (Pubitemid 26153157)
11. Hughes JL, Lackie PM, Wilson SJ, et al. Reduced structural proteins in the conjunctival epithelium in allergic eye disease. Allergy 2006;61:1268-74 (Pubitemid 44465585)
12. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115: 118-22 (Pubitemid 40075430)
13. Wan H, Winton HL, Soeller C, et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy 2001; 31:279-94 (Pubitemid 32231861)
14. Megens AAHP, Awouters J, Vermeire J. In vivo antiallergic activity of R87314 and R89674 in the Ascaris allergy test in dogs: a comparison with noberas-tine, loratadine, and terfenadine. Janssen Research Foundation PreClinical Research Report N109428/1 (February 1995). 1995
15. Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Design Dev Ther 2011;5:1-8
16. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84-8 (Pubitemid 20031417)
17. Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26:35-47 (Pubitemid 38241521)
18. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunc-tivitis. Clin Ther 2003;25:931-47 (Pubitemid 36459699)
19. Torkildsen GL, Williams JI, Abelson MB, et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol 2010;105:57-64
20. Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 2011;4:1-7
21. LASTACAFT (alcaftadine ophthalmic solution) 0.25% [prescribing information]. Jacksonville, Fl: Vistakon Pharmaceuticals, LLC, 2010
22. Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep 2003;3:363-8 (Pubitemid 38914984)
23. Torkildsen G, Gomes P, Williams J, et al. Evaluation of bepotastine besilate ophthalmic solution 1.0% in the conjunctival allergen challenge model of allergic conjunctivitis. 112th Annual Meeting of the American Academy of Ophthalmology. Atlanta, GA, 2008
24. Abelson MB, Gomes PJ, Pasquine T, et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc 2007;28:427-33